The Gut Microbiota and Irritable Bowel Syndrome: Friend or Foe?
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Progress in the understanding of the pathophysiology of irritable bowel syndrome (IBS), once thought to be a purely psychosomatic disease, has advanced considerably and low-grade inflammation and changes in the gut microbiota now feature as potentially important. The human gut harbours a huge microbial ecosystem, which is equipped to perform a variety of functions such as digestion of food, metabolism of drugs, detoxification of toxic compounds, production of essential vitamins, prevention of attachment of pathogenic bacteria to the gut wall, and maintenance of homeostasis in the gastrointestinal tract. A subset of patients with IBS may have a quantitative increase in bacteria in the small bowel (small intestinal bacterial overgrowth). Qualitative changes in gut microbiota have also been associated with IBS. Targeting the gut microbiota using probiotics and antibiotics has emerged as a potentially effective approach to the treatment of this, hitherto enigmatic, functional bowel disorder. The gut microbiota in health, quantitative and qualitative microbiota changes, and therapeutic manipulations targeting the microbiota in patients with IBS are reviewed in this paper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182 · cited 4×
“Reg III γ strengthens the intestinal epithelial barrier by inhibiting Gram-negative pathogens but has no effect on Gram-positive bacteria; its inhibition results, therefore, in a favourable environment for enteric pathogens to proliferate [4, 7, 55].”
BackgroundInfluentialThe functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
A microbial symbiosis factor prevents intestinal inflammatory disease
Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008) · Nature · doi:10.1038/nature07008 · Cited by 2,340
Gaboriau-Routhiau, V., Rakotobe, S., Lécuyer, E., Mulder, I., Lan, A., Bridonneau, C., Rochet, V., Pisi, A., De Paepe, M., Brandi, G., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.020 · Cited by 1,452 · cited 1×
“Thus, the gut microbiota plays an important role in the maintenance of homeostasis of various subpopulations of T cells: regulatory T cells (Tregs), T helper 1 (Th1), and T 17 (Th17) cells in the gut [79].”
BackgroundO’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Self-citationRajilić–Stojanović, M., Biagi, E., Heilig, H. G. H. J., Kajander, K., Kekkonen, R. A., Tims, S., & de Vos, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.043 · Cited by 1,041
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 1×
“3%) [89, 103, 105].”
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Vaishnava, S., Behrendt, C. L., Ismail, A. S., Eckmann, L., & Hooper, L. V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808723105 · Cited by 1,019
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002 · cited 2×
“The human gut is first colonized at birth; this microbiota gradually increases in size and diversity up to the end of the first year of life; by that time, the gut microbiota has come to resemble that of the adult and remains relatively stable thereafter [4].”
BackgroundMalinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699 · cited 1×
“The small intestine consists of mainly Gram-positive and aerobic bacteria, whereas the large intestine consists largely of Gramnegative and strictly anaerobic bacteria [5, 6].”
BackgroundGastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome
Saulnier, D. M., Riehle, K., Mistretta, T., Diaz, M., Mandal, D., Raza, S., Weidler, E. M., Qin, X., Coarfa, C., Milosavljevic, A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.072 · Cited by 672 · cited 1×
“Higher levels of these cytokines have been reported in IBS patients [34, 35].”
BackgroundSmall intestinal bacterial overgrowth syndrome
Bures, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i24.2978 · Cited by 620
SILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551
Piche, T., Barbara, G., Aubert, P., Bruley des Varannes, S., Dainese, R., Nano, J. L., Cremon, C., Stanghellini, V, De Giorgio, R., Galmiche, J. P., et al. (2009) · Gut · doi:10.1136/gut.2007.140806 · Cited by 540
Anderson, R. C., Cookson, A. L., McNabb, W. C., Park, Z., McCann, M. J., Kelly, W. J., & Roy, N. C. (2010) · BMC Microbiology · doi:10.1186/1471-2180-10-316 · Cited by 510
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499 · cited 7×
“Qualitative or quantitative changes in the microbiota of small intestine may lead to the clinical features of SIBO [56, 57].”
BackgroundMethodInfluentialIncreased mast cells in the irritable bowel syndrome
O’Sullivan, Clayton, Breslin, Harman, Bountra, Mclaren, & O’Morain (2000) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2000.00221.x · Cited by 480
Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes
Dunlop, S. P., Hebden, J., Campbell, E., Naesdal, J., Olbe, L., Perkins, A. C., & Spiller, R. C. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00672.x · Cited by 476
tana, C., umesaki, Y., imaoka, A., handa, T., kanazawa, M., & fukudo, S. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01427.x · Cited by 474 · cited 1×
“Malabsorption of carbohydrates may cause increased production of hydrogen gas, which is associated mainly with diarrhea-predominant IBS (IBS-D) [16] whilst excess methane gas production is associated with constipation-predominant IBS (IBS-C) [14].”
BackgroundKim, H. J., Camilleri, M., Mckinzie, S., Lempke, M. B., Burton, D. D., Thomforde, G. M., & Zinsmeister, A. R. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01543.x · Cited by 468 · cited 1×
“A randomized controlled trial showed that the oral administration of VSL#3, twice daily for 8 weeks, significantly reduced abdominal bloating, but not other parameters (colonic transit time, bowel dysfunction, abdominal pain, flatulence, or urgency) in a subgroup of diarrhea predominant IBS patients, when compared wit…”
ResultTHABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466 · cited 1×
“The risk of IBS increased sixfold after an acute gastrointestinal infection and persists for up to 3 years [44, 45].”
BackgroundGwee, K.-A. (2003) · Gut · doi:10.1136/gut.52.4.523 · Cited by 415 · cited 14×
“Recent studies have suggested that PI-IBS is associated with dysbiosis in the gut (induced either by enteric infection or by the use of antibiotics), psychological factors (such as stress, anxiety, and depression), genetic susceptibility of the host, persistent activation of the host immune system, increased intestina…”
BackgroundResultInfluentialSelf-citationKim, H. J., Vazquez Roque, M. I., Camilleri, M., Stephens, D., Burton, D. D., Baxter, K., Thomforde, G., & Zinsmeister, A. R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00695.x · Cited by 400 · cited 1×
“In a second study targeting 48 IBS patients with bloating, VSL#3 significantly reduced flatulence and colonic transit compared with the placebo group [93].”
BackgroundSmall Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome
Lin, H. C. (2004) · JAMA · doi:10.1001/jama.292.7.852 · Cited by 396 · cited 1×
“As discussed in previous sections, accumulating data support the role of bacteria in the etiology of IBS [102–104], and studies using antibiotics to target the intestinal microbiota to treat IBS are now emerging.”
ResultPostinfectious Irritable Bowel Syndrome-A Meta-Analysis
Halvorson, H. A., Schlett, C. D., & Riddle, M. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00654.x · Cited by 352
Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.031 · Cited by 351 · cited 1×
“[121]”
Kerckhoffs, A. P., Samsom, M., Rest, M. E. V. D., Vogel, J. D., Knol, J., Ben-Amor, K., & Akkermans, L. M. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2887 · Cited by 289
Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives
Salonen, A., de Vos, W. M., & Palva, A. (2010) · Microbiology · doi:10.1099/mic.0.043257-0 · Cited by 264 · cited 1×
“Several studies using different methodologies to define changes in the microbiota have been published, including classic culture-based techniques, PCR-based molecular technologies such as real-time PCR (q PCR), microarray, DGGE (denaturation gradient gel electrophoresis), GC profiling, and high-throughput sequencing b…”
BackgroundVillani, A., Lemire, M., Thabane, M., Belisle, A., Geneau, G., Garg, A. X., Clark, W. F., Moayyedi, P., Collins, S. M., Franchimont, D., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.049 · Cited by 244 · cited 3×
“Potentially harmful microorganisms and their metabolites cause the disruption of tight junctions between epithelial cells leading to increased mucosal permeability during the acute phase of infection [48, 49].”
BackgroundA Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome
Codling, C., O’Mahony, L., Shanahan, F., Quigley, E. M. M., & Marchesi, J. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0934-x · Cited by 243
Self-citationApathogenic, intestinal, segmented, filamentous bacteria stimulate the mucosal immune system of mice
Klaasen, H. L., Van der Heijden, P. J., Stok, W., Poelma, F. G., Koopman, J. P., Van den Brink, M. E., Bakker, M. H., Eling, W. M., & Beynen, A. C. (1993) · Infection and Immunity · doi:10.1128/iai.61.1.303-306.1993 · Cited by 231 · cited 1×
“These antimicrobial peptides destroy pathogenic bacteria by forming a pore in the bacterial cell wall [7, 55, 76].”
BackgroundIntestinal microecology and quality of life in irritable bowel syndrome patients
Si, J.-M. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i12.1802 · Cited by 218 · cited 1×
“[111]”
Differential Expression of Toll-Like Receptors in Patients With Irritable Bowel Syndrome
Brint, E. K., MacSharry, J., Fanning, A., Shanahan, F., & Quigley, E. M. M. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.438 · Cited by 205
Self-citationCarroll, I. M., Chang, Y.-H., Park, J., Sartor, R. B., & Ringel, Y. (2010) · Gut Pathogens · doi:10.1186/1757-4749-2-19 · Cited by 203 · cited 1×
“For example, a significantly increased quantity of aerobic bacteria and Lactobacillus was noted in IBS-D in feces but not in mucosal samples [19].”
BackgroundLee, K. J., Kim, Y. B., Kim, J. H., Kwon, H. C., Kim, D. K., & Cho, S. W. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05574.x · Cited by 171 · cited 2×
“As a result of increased permeability of intestinal epithelial cells, an influx of immune cells including mast cells, T lymphocytes, macrophages, and inflammatory mediators such as IL-2, IL-1β, IL-6, IL10, TGF-β occurs after an acute enteric infection [48, 49, 52, 53].”
BackgroundParkes, G. C., Brostoff, J., Whelan, K., & Sanderson, J. D. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01869.x · Cited by 167 · cited 3×
“Recent studies have suggested that PI-IBS is associated with dysbiosis in the gut (induced either by enteric infection or by the use of antibiotics), psychological factors (such as stress, anxiety, and depression), genetic susceptibility of the host, persistent activation of the host immune system, increased intestina…”
BackgroundT-Cell Activation in Patients With Irritable Bowel Syndrome
Öhman, L., Isaksson, S., Lindmark, A.-C., Posserud, I., Stotzer, P.-O., Strid, H., Sjövall, H., & Simrén, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.116 · Cited by 165 · cited 2×
“Increased concentrations of IL-1β are associated with the development of IBS symptoms such as alteration in bowel habits [81].”
BackgroundLyra, A., Rinttilä, T., Nikkilä, J., Krogius-Kurikka, L., Kajander, K., Malinen, E., Mättö, J., Mäkelä, L., & Palva, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5936 · Cited by 160 · cited 1×
“Malabsorption of carbohydrates may cause increased production of hydrogen gas, which is associated mainly with diarrhea-predominant IBS (IBS-D) [16] whilst excess methane gas production is associated with constipation-predominant IBS (IBS-C) [14].”
BackgroundMaukonen, J., Satokari, R., Mättö, J., Söderlund, H., Mattila-Sandholm, T., & Saarela, M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46134-0 · Cited by 156
New insights into the pathogenesis and pathophysiology of irritable bowel syndrome
Öhman, L., & Simrén, M. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.10.014 · Cited by 155
Grover, M., Kanazawa, M., Palsson, O. S., Chitkara, D. K., Gangarosa, L. M., Drossman, D. A., & Whitehead, W. E. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01142.x · Cited by 111
Functional Gastrointestinal Disorders Diagnosed by Rome III Questionnaire in Korea
Park, J. M., Choi, M.-G., Cho, Y. K., Lee, I. S., Kim, J. I., Kim, S. W., & Chung, I.-S. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.3.279 · Cited by 95 · cited 1×
“Alterations in the normal gutmicrobiota have been suggested as etiologic factors in the development of functional gastrointestinal disorders such as IBS and functional dyspepsia, common GI disorders of unknown etiology [7–9].”
BackgroundPharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome
Chey, W. D., Maneerattaporn, M., & Saad, R. (2011) · Gut and Liver · doi:10.5009/gnl.2011.5.3.253 · Cited by 89
Functional findings in irritable bowel syndrome
Posserud, I. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i18.2830 · Cited by 83
Vanner, S. (2008) · Gut · doi:10.1136/gut.2007.133629 · Cited by 78
Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome
Hong, K. S., Kang, H. W., Im, J. P., Ji, G. E., Kim, S. G., Jung, H. C., Song, I. S., & Kim, J. S. (2009) · Gut and Liver · doi:10.5009/gnl.2009.3.2.101 · Cited by 75
Altered intestinal microbiota in irritable bowel syndrome: Microbiota in IBS
Lee, K. J., & Tack, J. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01482.x · Cited by 69 · cited 4×
“The limitations of this test however include invasiveness and the challenges posed by attempting to culture all strains and species [54, 57]; therefore, hydrogen breath tests (GHBT or LHBT) are most commonly used [59].”
BackgroundMethodInfluential
Cited by
Human gut microbiota/microbiome in health and diseases: a review
Gomaa, E. Z. (2020) · Antonie van Leeuwenhoek · doi:10.1007/s10482-020-01474-7 · Cited by 1,294
Guinane, C. M., & Cotter, P. D. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13482996 · Cited by 846
Camilleri, M., Lasch, K., & Zhou, W. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00155.2012 · Cited by 396
RETRACTED ARTICLE: Role of the gut microbiome in chronic diseases: a narrative review
Vijay, A., & Valdes, A. M. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00991-6 · Cited by 361
RetractedDietary polyphenol impact on gut health and microbiota
Wan, M. L. Y., Co, V. A., & El-Nezami, H. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1744512 · Cited by 325
Metadata
- Authors
- Ghoshal, U. C., Shukla, R., Ghoshal, U., Gwee, K.-A., Ng, S. C., & Quigley, E. M. M.
- Venue
- International Journal of Inflammation
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-13
- ISSN
- 2042-0099 (ISSN-L)
- 2090-8040
- OpenAlex
- W2008702380
- Cited by
- 144
- References
- 48
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.